18
Participants
Start Date
April 25, 2023
Primary Completion Date
February 8, 2024
Study Completion Date
February 8, 2024
Insulin icodec
Participants will receive subcutaneously fixed dose of insulin icodec (700 U/mL) that is 5.6 U/kg bodyweight.
UBMD Peds-Div of Endo/Diabetes, Buffalo
John Hopkins Univ Hosp, Baltimore
University of Virginia Clinical Research Unit, Charlottesville
University of Virginia, Charlottesville
Nemours Children's Health, Jacksonville
Nemours Chld Clnc Jacksonville, Jacksonville
Nationwide Children's Hospital, Columbus
Cincinnati Child's Hsp Med Ctr, Cincinnati
Pennington Biom Res Ctr, Baton Rouge
Children's Hosp-Los Angeles, Los Angeles
Children's Hospital Los Angeles - Endocrinology, Los Angeles
Yale New Haven Hospital, Hospital Research Unit, New Haven
Yale University, New Haven
Lead Sponsor
Novo Nordisk A/S
INDUSTRY